Efficacy News and Research

RSS

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD).

10 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Red LED irradiation promotes cell transplantation in treatment of hypoxic-ischemic brain damage

A series of previous studies suggested that the neuronal differentiation rate of bone marrow mesenchymal stem cells during the in vitro culture reached 78-92%, but their in vivo transplantation efficiency, and survival and differentiation rates were very low.

10 Apr 2014

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Wednesday, April 9, 2014 at the American Association of Cancer Researchers conference in San Diego, CA.

10 Apr 2014

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma.

10 Apr 2014

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned.

10 Apr 2014

UCSF launches Brain Health Registry to advance neuroscience research

A new online project led by researchers at UC San Francisco promises to dramatically cut the time and cost of conducting clinical trials for brain diseases, while also helping scientists analyze and track the brain functions of thousands of volunteers over time.

9 Apr 2014

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.

9 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Green tea extract enhances cognitive functions in brain

Green tea is said to have many putative positive effects on health. Now, researchers at the University of Basel are reporting first evidence that green tea extract enhances the cognitive functions, in particular the working memory.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Efficacy News and Research

New edition of RADAR includes review of glycopyrronium for COPD treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Red LED irradiation promotes cell transplantation in treatment of hypoxic-ischemic brain damage

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Stem cells culled from bone marrow may prove beneficial in stroke recovery

UCSF launches Brain Health Registry to advance neuroscience research

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

Researchers identify novel compound effective against drug-resistant lung cancer

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Green tea extract enhances cognitive functions in brain

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Researchers use ultrasound to destroy cancerous tissue in brain

Women who had radiotherapy for breast cancer may have increased risk of lung tumour

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News